GlassScriptPhysician profile
Charles S Burke
NPI 1164408175
$733.34
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.10 · 2020: $14.50 · 2021: $74.80 · 2022: $167 · 2023: $164 · 2024: $118 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Abbvie INC. | $115.63 | 2021-2025 | |
| Corium, LLC | $92.46 | 2023-2025 | Azstarys |
| Alkermes, INC. | $73.22 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $59.40 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $58.43 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.91 | 2022 | |
| Allergan, INC. | $31.50 | 2019 | |
| Neurocrine Biosciences, INC. | $25.54 | 2021-2025 | |
| Neos Therapeutics, LP | $25.35 | 2019-2021 | |
| Tris Pharma INC | $17.49 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.30 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $16.02 | 2025 | Cobenfy |
| Eisai INC. | $15.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.